Type 2 diabetes (T2D), which is characterized by insulin resistance of target tissues (fat, skeletal muscle, liver) and, ultimately, impaired insulin secretion from the pancreatic β cell (6–8), is strongly associated with NASH: 44% of patients with NASH have T2D, and 37% of patients with T2D have NASH (9–11). This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.